Sökning: WFRF:(Malmberg B.) >
A randomised study ...
-
Lindman, HenrikUppsala universitet,Experimentell och klinisk onkologi,Uppsala University Hospital
(författare)
A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1)
- Artikel/kapitelEngelska2018
Förlag, utgivningsår, omfång ...
Nummerbeteckningar
-
LIBRIS-ID:oai:lup.lub.lu.se:8bd2a596-d3ff-40c8-a87e-372d08c86459
-
https://lup.lub.lu.se/record/8bd2a596-d3ff-40c8-a87e-372d08c86459URI
-
https://doi.org/10.1016/j.ejca.2018.02.016DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-352580URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:137973398URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:art swepub-publicationtype
-
Ämneskategori:ref swepub-contenttype
Anmärkningar
-
Study aim: Retrospective studies have demonstrated a worse outcome in breast cancer patients not developing leukopenia during adjuvant chemotherapy. The SBG 2000-1 is the first randomised trial designed to compare individually dosed chemotherapy without G-CSF support based on grade of toxicity to standard-dosed chemotherapy based on body surface area (BSA). Methods: Patients with early breast cancer were included and received the first cycle of standard FEC (fluorouracil 600 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 600 mg/m2). Patients with nadir leukopenia grade 0–2 after first cycle were randomised between either 6 additional courses of tailored FEC with increased doses (E 75–90 mg/m2, C 900–1200 mg/m2) or fixed treatment with 6 standard FEC. Patients with grade 3–4 leukopenia were registered and treated with 6 standard FEC. Primary end-point was distant disease-free survival (DDFS). Results: The study enrolled 1535 patients, of which 1052 patients were randomised to tailored FEC (N = 524) or standard FEC (N = 528), whereas 401 patients with leukopenia grade 3–4 continued standard FEC and formed the registered cohort. Dose escalation did not statistically significantly improve 10-year DDFS (79% and 77%, HR 0.87, CI 0.67–1.14, P = 0.32) or OS (82% and 78%, respectively, HR 0.89, CI 0.57–1.16, P = 0.38). Corresponding estimates for the registered group of patients were DDFS 79% and OS 82%, respectively. Conclusions: The SBG 2000-1 study failed to show a statistically significant improvement of escalated and tailored-dosed chemotherapy compared with standard BSA-based chemotherapy in patients with low haematological toxicity, although all efficacy parameters showed a numerical advantage for tailored treatment.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Andersson, M.Copenhagen University Hospital,Rigshosp, Dept Oncol, Copenhagen, Denmark
(författare)
-
Ahlgren, J.Gävle Hospital,Gavle Cent Hosp, Dept Oncol, Gavle, Sweden;Orebro Univ Hosp, Dept Oncol, Orebro, Sweden,Aarhus Univ Hosp, Dept Oncol, Aarhus, Denmark,Aarhus University Hospital
(författare)
-
Balslev, E.Herlev Hospital,Herlev Hosp, Dept Oncol, Herlev, Denmark,Rigshosp, Dept Oncol, Copenhagen, Denmark,Copenhagen University Hospital
(författare)
-
Sverrisdottir, A.Stockholm South General Hospital,Soder Sjukhuset, Dept Oncol, Stockholm, Sweden;Landspitali, Dept Oncol, Reykjavik, Iceland
(författare)
-
Holmberg, S. B.Sahlgrenska University Hospital,Dept Surg, Molndal, Sweden
(författare)
-
Bengtsson, N. O.Umeå University,Umea Univ Hosp, Dept Oncol, Umea, Sweden
(författare)
-
Jacobsen, E. H.Vejle Hospital,Vejle Hosp, Dept Oncol, Vejle, Denmark,Vasteras Hosp, Dept Oncol, Vasteras, Sweden;Aalborg Univ Hosp, Dept Oncol, Aalborg, Denmark,Västmanland Hospital
(författare)
-
Jensen, A. B.Karolinska Institute,Karolinska Institutet,Karolinska University Hospital
(författare)
-
Hansen, J.Västmanland Hospital
(författare)
-
Tuxen, M. K.Herlev Hospital,Herlev Hosp, Dept Oncol, Herlev, Denmark
(författare)
-
Malmberg, L.Karlstad Hospital,Karlstad Hosp, Dept Oncol, Karlstad, Sweden;Boras Hosp, Dept Oncol, Boras, Sweden
(författare)
-
Villman, K.Örebro University Hospital,Orebro Univ Hosp, Dept Oncol, Orebro, Sweden
(författare)
-
Anderson, H.Lund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund Univ, Dept Clin Sci, Div Canc Epidemiol, Lund, Sweden(Swepub:lu)onk-han
(författare)
-
Ejlertsen, B.Copenhagen University Hospital
(författare)
-
Bergh, J.Karolinska Institute,Karolinska University Hospital
(författare)
-
Blomqvist, C.Uppsala universitet,Institutionen för immunologi, genetik och patologi,Orebro Univ Hosp, Dept Oncol, Orebro, Sweden,Uppsala University Hospital
(författare)
-
Uppsala universitetExperimentell och klinisk onkologi
(creator_code:org_t)
-
Swedish Breast Cancer Group (SweBCG)
-
Danish Breast Cancer Group (DBCG)
-
Scandinavian Breast Cancer Group (SBG)
Sammanhörande titlar
-
Ingår i:European Journal of Cancer: Elsevier BV94, s. 79-860959-80491879-0852
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Lindman, Henrik
-
Andersson, M.
-
Ahlgren, J.
-
Balslev, E.
-
Sverrisdottir, A ...
-
Holmberg, S. B.
-
visa fler...
-
Bengtsson, N. O.
-
Jacobsen, E. H.
-
Jensen, A. B.
-
Hansen, J.
-
Tuxen, M. K.
-
Malmberg, L.
-
Villman, K.
-
Anderson, H.
-
Ejlertsen, B.
-
Bergh, J.
-
Blomqvist, C.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
European Journal ...
- Av lärosätet
-
Lunds universitet
-
Uppsala universitet
-
Karolinska Institutet